1. Velavan TP, Pallerla SR, Rüter J, Augustin Y,
Kremsner PG, Krishna S, et al. Host genetic factors
determining COVID-19 susceptibility and severity.
EBioMedicine. 2021;72.
2. Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2):
an update. Cureus. 2020;12 (3.)
3. Rajpal VR, Sharma S, Sehgal D, Singh A, Kumar A,
Vaishnavi S, et al. A comprehensive account of
SARS-CoV-2 genome structure, incurred mutations,
lineages and COVID-19 vaccination program. JVI .
2022;17(9):687-706.
4. Hardenbrook NJ, Zhang P. A structural view of the
SARS-CoV-2 virus and its assembly. COVIRO .
2022;52:123-34.
5. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms
of SARS-CoV-2 entry into cells.
Nat.Rev.Mol.Cell.Biol . 2022;23(1):3-20.
6. Rodrigues L, Bento Cunha R, Vassilevskaia T,
Viveiros M, Cunha C. Drug repurposing for COVID-
19: A review and a novel strategy to identify new
targets and potential drug candidates.Mol.
2022;27(9):272 3.
7. Islam MJ, Islam NN, Alom MS, Kabir M, Halim MA.
A Review on structural, non-structural, and accessory
proteins of SARS-CoV-2: Highlighting drug target
sites. Immunobiology. 2022:152302.
8. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V.
Coronavirus biology and replication: implications for
SARS-CoV-2. Nat.Microbiol . 2021;19(3):155-70.
9. Ortiz-Fernández L, López-Mejias R, Carmona FD,
Castaño-Nuñez AL, Lyons PA, Caruz A, et al. The
role of a functional variant of Tyk2 in vasculitides and
infections. Clin.Exp.Rheumatol , 2020, vol 38, num 5,
p 949-955. 2020.
10.Zhao X, Chen D, Li X, Griffith L, Chang J, An P, et
al. Interferon control of human coronavirus infection
and viral evasion: mechanistic insights and
implications for antiviral drug and vaccine
development. J.Mol.Biol . 2022;434(6):167438.
11.Yassine HM, Emara M, Mbarek H, Marr N, Haddad-
Boubaker S. Personalized medicine and infectious
disease management: Front.Med SA; 2023.
12.Tran NV, Nguyen LTA, Lim KW, Phan AT. Potent
and selective knockdown of tyrosine kinase 2 by
antisense oligonucleotides. Immunohorizons.
2021;5(2):70-80.
13.Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H.
The SARS-CoV-2 spike glycoprotein biosynthesis,
structure, function, and antigenicity: implications for
the design of spike-based vaccine immunogens.
Front.Immunol . 2020;11:576622.
14.Zabihi Rizi F, Ghorbani A, Zahtab P, Darbaghshahi
NN, Ataee N, Pourhamzeh P, et al. TYK2 single-
nucleotide variants associated with the severity of
COVID-19 disease. Arch. Virol . 2023;168(4):119.
15.Ragimbeau J, Dondi E, Alcover A, Eid P, Uzé G,
Pellegrini S. The tyrosine kinase Tyk2 controls
IFNAR1 cell surface expression. EMBO J. 2003 Feb
3;2 2(3:)47-537. PubMed PMID: 12554654. Pubmed
Central PMCID: PMC140723. Epub 2003/01/30. eng.
16.Wang Y, Guga S, Wu K, Khaw Z, Tzoumkas K,
Tombleson P, et al. COVID-19 and systemic lupus
erythematosus genetics: A balance between
autoimmune disease risk and protection against
infection. PLoS Genet . 2022;18(11):e1010253.
17.Sarrafzadeh SA, Mahloojirad M, Casanova J-L,
Badalzadeh M, Bustamante J, Boisson-Dupuis S, et al.
A new patient with inherited TYK2 deficiency.
Clin.Immunol . 2020;40 :5-232.
18.Boisson-Dupuis S, Ramirez-Alejo N, Li Z, Patin E,
Rao G, Kerner G, et al. Tuberculosis and impaired IL-
23–dependent IFN-γ immunity in humans
homozygous for a common TYK2 missense variant.
Sci.immunol . 2018;3(30):eaau8714.
19.Wu P, Chen S, Wu B, Chen J, Lv G. A TYK2 gene
mutation c. 2395G> A leads to TYK2 deficiency: a
case report and literature review. J.Pediatr .
2020;8:253.
20.Verma A, Tsao NL, Thomann LO, Ho Y-L, Iyengar
SK, Luoh S-W, et al. A Phenome-Wide Association
Study of genes associated with COVID-19 severity
reveals shared genetics with complex diseases in the
Million Veteran Program. PLoS genet .
2022;18(4):e1010113.
21.Moncada Vélez M, Kreins AY, Ciancanelli M,
Okada S, Kong X-F, Ramírez Alejo N, et al. Human
TYK2 Deficiency: Mycobacterial and Viral Infections
without Hyper-IgE Syndrome. 2015.22.Guo W, Feng X, Yang M, Shangguan Y, Shi P, Wang
S, et al. Mycobacterium intracellulare infection
associated with TYK2 deficiency: a case report and
review of the literature. Infect.Drug.Resist .
2020:4347-53.
23.Steffen BT, Pankow JS, Lutsey PL, Demmer RT,
Misialek JR, Guan W, et al. Proteomic profiling
identifies novel proteins for genetic risk of severe
COVID-19: the Atherosclerosis Risk in Communities
Study.Hum.Mol . Genet . 2022;31(14):2452-61.
24.Akbari M, Akhavan-Bahabadi M, Shafigh N,
Taheriazam A, Hussen BM, Sayad A, et al. Expression
analysis of IFNAR1 and TYK2 transcripts in COVID-
19 patients. Cytokine. 2022;153:155849.
25.Dieter C ,de Almeida Brondani L, Lemos NE,
Schaeffer AF, Zanotto C, Ramos DT, et al.
Polymorphisms in ACE1, TMPRSS2, IFIH1,
IFNAR2, and TYK2 genes are associated with worse
clinical outcomes in COVID-19. Genes.
2022;14(1):29.
26.Benmansour R, Tagajdid M, Elkochri S, Aabi R,
Elannaz H, Laraqui A, et al. Genetic Susceptibility to
Severe Forms of COVID-19: What we Learned in
2022. Saudi J.Pathol.Microbiol . 2023;8(4):90-8.
27.Diogo D, Bastarache L, Liao KP, Graham RR, Fulton
RS, Greenberg JD, et al. TYK2 protein-coding
variants protect against rheumatoid arthritis and
autoimmunity, with no evidence of major pleiotropic
effects on non-autoimmune complex traits. PloS one.
2015;10(4):e0122271.
28.Dendrou CA, Cortes A, Shipman L, Evans HG,
Attfield KE, Jostins L, et al .Resolving TYK2 locus
genotype-to-phenotype differences in autoimmunity.
Sci.Transl.Med. 2016;8(363):363ra149-363ra149.
29.Huang Y-X, Tian T, Huang J-X, Wang J, Sui C, Ni
J. A shared genetic contribution to osteoarthritis and
COVID-19 outcomes: a large-scale genome-wide
cross-trait analysis.Front.Immunol. 2023;14:1184958.
30.Pairo-Castineira E, Clohisey S, Klaric L, Bretherick
AD, Rawlik K, Pasko D, et al. Genetic mechanisms of
critical illness in COVID-19. Nature.
2021;591(7 848:)8-92.
31.Ji X-S, Chen B, Ze B, Zhou W-H. Human genetic
basis of severe or critical illness in COVID-19. Front
.Cell.Infect.Microbiol . 2022;12:963239.
32.Boutin S, Hildebrand D, Boulant S, Kreuter M, Rüter
J, Pallerla SR, et al .Host factors facilitating SARS‐
CoV‐2 virus infection and replication in the lungs.
Cell.Mol.Life Sci . 2021;78:5953-76.